Now showing items 1-10 of 18
Multilocus analysis of SNP and metabolic data within a given pathway
(BioMed Central, 2006-01-13)
Background: Complex traits, which are under the influence of multiple and possibly interacting genes, have become a subject of new statistical methodological research. One of the greatest challenges facing human geneticists ...
Low expression levels of ATM may substitute for CHEK2 / TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
(BioMed Central, 2012-03-15)
<p>Introduction: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNAdamaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 ...
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
(BioMed Central, 2012-08-14)
<p>Introduction: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to ...
Inflammatory biomarkers with focus on Calprotectin (S100A8/S100A9) and S100A12 (EN-RAGE) : method development and application in acute radiation proctitis and rheumatoid arthritis patients
(The University of Bergen, 2007-02-02)
Assessments of diseases are usually performed by a combination of clinical symptoms, signs and objective measurements. Biochemical markers of inflammation are important in evaluation of treatment of acute and chronic ...
Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters
(BioMed Central, 2006-10-20)
Background: The tumor suppressor gene p53 (TP53) controls numerous signaling pathways and is frequently mutated in human cancers. Novel p53 isoforms suggest alternative splicing as a regulatory feature of p53 ...
MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk
(Public Library of Science, 2012-04-30)
The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been ...
Adjuvant treatment: the contribution of expression microarrays
(BioMed Central, 2007-12-20)
Radiation therapy combined with hormone treatment for primary prostate cancer. Effects of radiation dose escalations and assessment of side effects
(The University of Bergen, 2009-05-06)
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
(Public Library of Science, 2008-08-26)
Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis ...
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
(BioMed Central, 2012-10-05)
<p>Background: While BRCA mutation carriers possess a 20-40% lifetime risk of developing ovarian cancer, knowledge about genetic modifying factors influencing the phenotypic expression remains obscure. We explored the ...